Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.21
DVA's Cash to Debt is ranked lower than
59% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 0.36 vs. DVA: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
DVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.11 Max: 3.35
Current: 0.21
0.01
3.35
Equity to Asset 0.26
DVA's Equity to Asset is ranked lower than
78% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.46 vs. DVA: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
DVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.24 Max: 0.62
Current: 0.26
0.04
0.62
Interest Coverage 3.85
DVA's Interest Coverage is ranked lower than
66% of the 189 Companies
in the Global Medical Care industry.

( Industry Median: 6.08 vs. DVA: 3.85 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.65 Max: N/A
Current: 3.85
F-Score: 6
Z-Score: 2.07
M-Score: -2.71
WACC vs ROIC
5.55%
5.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.49
DVA's Operating margin (%) is ranked higher than
53% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 7.96 vs. DVA: 8.49 )
Ranked among companies with meaningful Operating margin (%) only.
DVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 8.49
8.49
17.15
Net-margin (%) 1.96
DVA's Net-margin (%) is ranked lower than
66% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 5.01 vs. DVA: 1.96 )
Ranked among companies with meaningful Net-margin (%) only.
DVA' s Net-margin (%) Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 7.25
Current: 1.96
1.96
7.25
ROE (%) 5.36
DVA's ROE (%) is ranked lower than
67% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 9.22 vs. DVA: 5.36 )
Ranked among companies with meaningful ROE (%) only.
DVA' s ROE (%) Range Over the Past 10 Years
Min: 5.37  Med: 20.55 Max: 27.64
Current: 5.36
5.37
27.64
ROA (%) 1.46
DVA's ROA (%) is ranked lower than
68% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.95 vs. DVA: 1.46 )
Ranked among companies with meaningful ROA (%) only.
DVA' s ROA (%) Range Over the Past 10 Years
Min: 1.49  Med: 4.86 Max: 5.69
Current: 1.46
1.49
5.69
ROC (Joel Greenblatt) (%) 39.00
DVA's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 18.85 vs. DVA: 39.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 38.04  Med: 56.94 Max: 68.47
Current: 39
38.04
68.47
Revenue Growth (3Y)(%) 15.10
DVA's Revenue Growth (3Y)(%) is ranked higher than
77% of the 172 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. DVA: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 15.10 Max: 39.8
Current: 15.1
4.8
39.8
EBITDA Growth (3Y)(%) -0.60
DVA's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. DVA: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.3  Med: 15.00 Max: 98.2
Current: -0.6
-25.3
98.2
EPS Growth (3Y)(%) -23.00
DVA's EPS Growth (3Y)(%) is ranked lower than
90% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. DVA: -23.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29  Med: 14.10 Max: 125.5
Current: -23
-29
125.5
» DVA's 10-Y Financials

Financials (Next Earnings Date: 2016-05-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

DVA Guru Trades in Q2 2015

Jim Simons 726,600 sh (+361.04%)
Steven Cohen 118,600 sh (+47.51%)
Ray Dalio 79,526 sh (+43.74%)
Paul Tudor Jones 4,700 sh (+34.29%)
Mario Gabelli 41,763 sh (+5.29%)
Manning & Napier Advisors, Inc 1,421,635 sh (+2.99%)
Warren Buffett 38,565,570 sh (unchged)
Steve Mandel 5,455,774 sh (unchged)
Pioneer Investments Sold Out
Alan Fournier 2,158,397 sh (-3.90%)
Arnold Van Den Berg 153,928 sh (-5.86%)
Andreas Halvorsen 4,968,551 sh (-21.91%)
» More
Q3 2015

DVA Guru Trades in Q3 2015

Joel Greenblatt 48,381 sh (New)
Arnold Van Den Berg 285,918 sh (+85.75%)
Steve Mandel 7,918,998 sh (+45.15%)
Mario Gabelli 41,763 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Warren Buffett 38,565,570 sh (unchged)
Steven Cohen Sold Out
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 1,405,605 sh (-1.13%)
Alan Fournier 1,999,797 sh (-7.35%)
Jim Simons 408,600 sh (-43.77%)
Andreas Halvorsen 2,735,075 sh (-44.95%)
» More
Q4 2015

DVA Guru Trades in Q4 2015

Ray Dalio 31,945 sh (New)
Paul Tudor Jones 20,656 sh (New)
Joel Greenblatt 302,502 sh (+525.25%)
Jim Simons 924,100 sh (+126.16%)
Manning & Napier Advisors, Inc 1,887,295 sh (+34.27%)
Warren Buffett 38,565,570 sh (unchged)
Steve Mandel Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 39,963 sh (-4.31%)
Arnold Van Den Berg 268,133 sh (-6.22%)
Alan Fournier 1,286,097 sh (-35.69%)
» More
Q1 2016

DVA Guru Trades in Q1 2016

Arnold Van Den Berg 328,908 sh (+22.67%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DaVita HealthCare Partners Inc

Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...
Steve Mandel Sells Health Care Stakes Guru sells holdings in Allergan and DaVita HealthCare Partners
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, sold out two health care stakes in the fourth quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 60.09
DVA's P/E(ttm) is ranked lower than
84% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 26.42 vs. DVA: 60.09 )
Ranked among companies with meaningful P/E(ttm) only.
DVA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.59  Med: 19.60 Max: 61.1
Current: 60.09
11.59
61.1
Forward P/E 16.58
DVA's Forward P/E is ranked higher than
52% of the 75 Companies
in the Global Medical Care industry.

( Industry Median: 16.81 vs. DVA: 16.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 60.09
DVA's PE(NRI) is ranked lower than
85% of the 177 Companies
in the Global Medical Care industry.

( Industry Median: 26.00 vs. DVA: 60.09 )
Ranked among companies with meaningful PE(NRI) only.
DVA' s PE(NRI) Range Over the Past 10 Years
Min: 11.63  Med: 19.51 Max: 61.1
Current: 60.09
11.63
61.1
Price/Owner Earnings (ttm) 200.31
DVA's Price/Owner Earnings (ttm) is ranked lower than
93% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 26.24 vs. DVA: 200.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.94  Med: 15.99 Max: 202.98
Current: 200.31
8.94
202.98
P/B 3.19
DVA's P/B is ranked lower than
60% of the 214 Companies
in the Global Medical Care industry.

( Industry Median: 2.52 vs. DVA: 3.19 )
Ranked among companies with meaningful P/B only.
DVA' s P/B Range Over the Past 10 Years
Min: 2.36  Med: 3.29 Max: 7.09
Current: 3.19
2.36
7.09
P/S 1.16
DVA's P/S is ranked higher than
63% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. DVA: 1.16 )
Ranked among companies with meaningful P/S only.
DVA' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.19 Max: 2.34
Current: 1.16
0.77
2.34
PFCF 18.71
DVA's PFCF is ranked higher than
54% of the 112 Companies
in the Global Medical Care industry.

( Industry Median: 20.31 vs. DVA: 18.71 )
Ranked among companies with meaningful PFCF only.
DVA' s PFCF Range Over the Past 10 Years
Min: 7.52  Med: 17.04 Max: 42.52
Current: 18.71
7.52
42.52
POCF 10.27
DVA's POCF is ranked higher than
67% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 14.87 vs. DVA: 10.27 )
Ranked among companies with meaningful POCF only.
DVA' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 9.57 Max: 17.87
Current: 10.27
5.22
17.87
EV-to-EBIT 19.26
DVA's EV-to-EBIT is ranked higher than
50% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 19.43 vs. DVA: 19.26 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.40 Max: 21.5
Current: 19.26
8.5
21.5
EV-to-EBITDA 12.53
DVA's EV-to-EBITDA is ranked higher than
56% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 13.63 vs. DVA: 12.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.80 Max: 17.1
Current: 12.53
6.8
17.1
PEG 6.48
DVA's PEG is ranked lower than
86% of the 76 Companies
in the Global Medical Care industry.

( Industry Median: 2.87 vs. DVA: 6.48 )
Ranked among companies with meaningful PEG only.
DVA' s PEG Range Over the Past 10 Years
Min: 0.41  Med: 1.30 Max: 5.27
Current: 6.48
0.41
5.27
Shiller P/E 32.17
DVA's Shiller P/E is ranked lower than
52% of the 44 Companies
in the Global Medical Care industry.

( Industry Median: 31.64 vs. DVA: 32.17 )
Ranked among companies with meaningful Shiller P/E only.
DVA' s Shiller P/E Range Over the Past 10 Years
Min: 19.65  Med: 30.60 Max: 70.02
Current: 32.17
19.65
70.02
Current Ratio 1.88
DVA's Current Ratio is ranked higher than
70% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. DVA: 1.88 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.83 Max: 4.1
Current: 1.88
0.39
4.1
Quick Ratio 1.80
DVA's Quick Ratio is ranked higher than
73% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. DVA: 1.80 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.75 Max: 4.1
Current: 1.8
0.37
4.1
Days Inventory 5.94
DVA's Days Inventory is ranked higher than
84% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 16.80 vs. DVA: 5.94 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6.00 Max: 8.61
Current: 5.94
3.72
8.61
Days Sales Outstanding 45.66
DVA's Days Sales Outstanding is ranked lower than
53% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 43.55 vs. DVA: 45.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 63.93 Max: 69.73
Current: 45.66
43.53
69.73
Days Payable 19.09
DVA's Days Payable is ranked lower than
79% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 43.92 vs. DVA: 19.09 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 21.11 Max: 27.1
Current: 19.09
14.92
27.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.03
DVA's Price/Projected FCF is ranked higher than
78% of the 87 Companies
in the Global Medical Care industry.

( Industry Median: 1.76 vs. DVA: 1.03 )
Ranked among companies with meaningful Price/Projected FCF only.
DVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.14 Max: 2.55
Current: 1.03
0.97
2.55
Price/DCF (Earnings Based) 4.97
DVA's Price/DCF (Earnings Based) is ranked lower than
100% of the 26 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. DVA: 4.97 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.97
DVA's Price/Median PS Value is ranked higher than
59% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 1.06 vs. DVA: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
DVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.33  Med: 1.01 Max: 2.21
Current: 0.97
0.33
2.21
Price/Peter Lynch Fair Value 5.20
DVA's Price/Peter Lynch Fair Value is ranked lower than
93% of the 46 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. DVA: 5.20 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 1.31 Max: 8.16
Current: 5.2
0.56
8.16
Earnings Yield (Greenblatt) (%) 5.14
DVA's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. DVA: 5.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8.00 Max: 11.8
Current: 5.14
4.7
11.8
Forward Rate of Return (Yacktman) (%) 16.65
DVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 102 Companies
in the Global Medical Care industry.

( Industry Median: 11.10 vs. DVA: 16.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.3  Med: 20.90 Max: 40.1
Current: 16.65
12.3
40.1

More Statistics

Revenue(Mil) $13782
EPS $ 1.23
Beta0.69
Short Percentage of Float2.39%
52-Week Range $61.36 - 84.40
Shares Outstanding(Mil)206.10

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 14,661 15,616
EPS($) 3.95 4.45
EPS without NRI($) 3.95 4.45

Business Description

Industry: Health Care Providers » Medical Care
Compare:XTER:FRE, NYSE:HCA, XTER:FMEA, XKLS:5225, NYSE:UHS » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Starting With GAAP Jun 11 2015 
Berkshire Hathaway: Business Value Exceeds Market Value May 26 2015 
Manning & Napier's Top 5 Stock Selections of Q1 Apr 21 2015 

More From Other Websites
DaVita HealthCare Partners Inc. Schedules 2016 Capital Markets Day Apr 26 2016
DaVita HealthCare Partners Inc. Schedules 1st Quarter 2016 Investor Conference Call Apr 26 2016
(TOFR) Playing Stock Splits with the TOFR ETF Apr 22 2016
Weekly CEO Sells Highlights Apr 18 2016
DaVita to Acquire Mountain View, Expand Footprint in Colorado Apr 11 2016
Mountain View Medical Group to Join DaVita HealthCare Partners Apr 08 2016
DaVita Kidney Care Releases Free Kidney-Friendly Cookbook Apr 07 2016
DAVITA HEALTHCARE PARTNERS INC. Files SEC form 8-K, Regulation FD Disclosure Apr 06 2016
UBS Says Buy Berkshire Hathaway: What You Need To Know Mar 29 2016
DaVita Kidney Care Revamps Customized Online Experience for Those Affected by Kidney Disease Mar 23 2016
DaVita HealthCare Partners Celebrates 10 Years Among FORTUNE Magazine's World's Most Admired... Mar 16 2016
5 Trade ideas for Monday: DaVita, Home Depot, Krispie Kreme, Northern Trust and PacWest Bancorp Mar 13 2016
Warren Buffett Moves Further Into Value Territory Mar 12 2016
DaVita Celebrates World Kidney Day and National Kidney Month Mar 10 2016
DaVita World Headquarters Awarded LEED Platinum Certification by U.S. Green Building Council Mar 09 2016
DAVITA HEALTHCARE PARTNERS INC. Financials Mar 03 2016
DaVita Closes Everett Buyout, Continues Inorganic Growth Mar 02 2016
DaVita Kidney Care Honors Physicians for Exemplifying Core Values Mar 02 2016
Everett Clinic, DaVita HealthCare complete $385M merger Mar 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK